Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Inclusion Criteria:

• Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound
• Birth weight ≥ 500g
• Singleton or twin birth

Exclusion Criteria:

-